{"commentary":{"count":43,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":34,"youtube":6,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05226117\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05226117","nct_id":"NCT05226117","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05226117. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients with muscle-invasive urothelial carcinoma of the bladder, who are suited for and accept radical cystectomy (RC)","label":"Treatment arm","type":"EXPERIMENTAL"}],"collaborators":["High Research"],"completion_date":{"date":"2025-09-24","type":"ACTUAL"},"conditions":["Urothelial Carcinoma"],"enrollment":{"count":44,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sacituzumab govitecan","type":"DRUG"}],"last_update":"2026-03-27","lead_sponsor":"IRCCS San Raffaele","official_title":"SURE-01_An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Sacituzumab Govitecan, Before Radical Cystectomy, for Patients With Muscleinvasive Bladder Cancer Who Cannot Receive or Refuse Cisplatin-based Chemotherapy","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-09-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathological complete response","timeFrame":"After the last cycle of the investigational drug (each cycle is 21 days)"}],"references":[{"citation":"Necchi A, de Jong JJ, Maiorano BA, Proudfoot JA, Basile G, Cigliola A, Mercinelli C, Tateo V, Piacentini M, Crupi E, Pastorino GL, Latini G, Tomasi E, Davicioni E, Moschini M, Brembilla G, Colecchia M, de Cobelli F, Ross JS, Madison R, Tambaoan CFB, Briganti A, Montorsi F. Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial. J Clin Oncol. 2026 Jul 20;44(21):2017-2028. doi: 10.1200/JCO-26-00142. Epub 2026 May 31.","pmid":"42218654","type":"DERIVED"}],"start_date":{"date":"2022-03-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT05226117"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05226117"}